A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
03/2011
03/17/2011	US20110065132 Identification of Actinobacillus actinomycetemcomitans Antigens for use in the Diagnosis, Treatment and Monitoring of Periodontal Diseases
03/17/2011	US20110065109 Rna interference mediating small rna molecules
03/17/2011	US20110064828 Treatment of metastatic tumors and other conditions
03/17/2011	US20110064819 Encapsulation of biologically active agents
03/17/2011	US20110064813 Use of salsalate with or without caffeine and with or without omega 3, and other pharmaceutical compounds in a distinctively unique nano-particulate capsule and tablet
03/17/2011	US20110064811 Solid forms of N-[2,4-BIS(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
03/17/2011	US20110064797 Capsule of thermogenic cells for treating a metabolic disease
03/17/2011	US20110064795 Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
03/17/2011	US20110064792 Method for Opening Tight Junctions
03/17/2011	US20110064786 Novel use of basic fibroblast growth factor in the de-differentiation of animal connective tissue cells
03/17/2011	US20110064770 Immunization of an Individual Against Carcinomas and the Preliminary Stages Thereof
03/17/2011	US20110064762 Protein a compositions and methods of use
03/17/2011	US20110064757 Nucleic acid molecules and polypeptides for immune modulation
03/17/2011	US20110064755 Methods for producing block copolymer/amphiphilic particles
03/17/2011	US20110064753 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
03/17/2011	US20110064752 Extracellular targeted drug conjugates
03/17/2011	US20110064751 Targeted immunoconjugates
03/17/2011	US20110064749 Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
03/17/2011	US20110064748 Pharmaceutical combination and method for treating tumor
03/17/2011	US20110064747 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)
03/17/2011	US20110064743 Human anti-cancer antibodies
03/17/2011	US20110064739 Medicament, compositions, and substances for treating and identifying adenocarcinoma of the lung
03/17/2011	US20110064738 Human anti-vegf polyclonal antibodies and uses thereof
03/17/2011	US20110064737 ErbB ANTAGONISTS FOR PAIN THERAPY
03/17/2011	US20110064736 Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
03/17/2011	US20110064735 Methods for treating lymphomas in certain patient populations and screening patients for said therapy
03/17/2011	US20110064734 Prevention and treatment of amyloidogenic disease
03/17/2011	US20110064733 Ca6 antigen-specific cytotoxic conjugate and methods of using the same
03/17/2011	US20110064732 Methods and compositions for diagnostic use in cancer patients
03/17/2011	US20110064717 Homing endonuclease genes and their targets
03/17/2011	US20110064715 Methods for determining oligosaccharide binding
03/17/2011	US20110064713 Methods of Treating Cancer Using Opioid Retargeted Endopepidases
03/17/2011	US20110064694 Anti-hepatitis c activity of meso-tetrakis-porphyrin analogues
03/17/2011	US20110064689 In situ immunization
03/17/2011	US20110064676 Diagnostic and therapeutic nanoparticles
03/17/2011	US20110064675 Elemental iron nanoparticles
03/17/2011	US20110064673 New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them
03/17/2011	US20110064670 Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
03/17/2011	US20110064664 Methods and compositions involving chitosan nanoparticles
03/17/2011	US20110064661 Non-radioactive phospholipid compounds, compositions, and methods of use
03/17/2011	US20110064660 Deuterated alkyl phospholipid compounds, compositions, and methods of use
03/17/2011	US20110064658 RGD-(bacterio)chlorophyll conjugates for photodynamic therapy and Imaging of Necrotic tumors
03/17/2011	US20110064654 Prostate cancer diagnosis and treatment
03/17/2011	US20110064653 Class I Anti-CEA Antibodies and Uses Thereof
03/17/2011	US20110064652 Nanoparticles for targeted delivery of active agents to the lung
03/17/2011	US20110064650 Microorganisms for preventing and treating neoplasms accompanying cellular therapy
03/17/2011	DE102010044854A1 Hemmung des Überlebens von Eierstockkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of ovarian cancer by cyclohexenone from Antrodia camphorata
03/17/2011	DE102010044852A1 Hemmung des Überlebens von Magenkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of gastric cancer by cyclohexenone from Antrodia camphorata
03/17/2011	DE102010044851A1 Hemmung des Überlebens von Blasenkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of bladder cancer by cyclohexenone from Antrodia camphorata
03/17/2011	DE102010044850A1 Hemmung des Überlebens von Kolorektalkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival from colorectal cancer by cyclohexenone from Antrodia camphorata
03/17/2011	DE102005041616B4 Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen Melanoma-associated MHC class I-associated oligopeptides and coding for these polynucleotides and uses thereof
03/17/2011	CA2774144A1 Oncolytic vaccinia virus combination cancer therapy
03/17/2011	CA2774140A1 Vaccines directed to langerhans cells
03/17/2011	CA2774099A1 6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof
03/17/2011	CA2773854A1 Pharmaceutically useful heterocycle-substituted lactams
03/17/2011	CA2773838A1 N-4(-((3-(2-amino-4pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
03/17/2011	CA2773665A1 Improved pseudomonas exotoxin a with reduced immunogenicity
03/17/2011	CA2773661A1 Ether derivatives of bicyclic heteroaryls
03/17/2011	CA2773614A1 Method of treating cancer by inhibiting trim59 expression or activity
03/17/2011	CA2773591A1 Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
03/17/2011	CA2773590A1 8-oxodihydropurine derivative
03/17/2011	CA2773579A1 Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4)
03/17/2011	CA2773561A1 Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
03/17/2011	CA2773494A1 Actriib antagonists and dosing and uses thereof
03/17/2011	CA2773182A1 Inhibitors of jak
03/17/2011	CA2772989A1 Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer
03/17/2011	CA2772579A1 Thioimidazolidinone androgen receptor antagonists and uses thereof
03/17/2011	CA2772411A1 Cancer stem cell-targeted and drug resistant cancer therapy
03/17/2011	CA2772261A1 Novel nucleoside phosphonates and analogs
03/17/2011	CA2772120A1 Use of metformin in cancer treatment and prevention
03/17/2011	CA2772068A1 Methods for treatment of a sarcoma using an epimetabolic shifter (coenzyme q10)
03/17/2011	CA2771675A1 Ortho substituted pyrimidine compounds as jak inhibitors
03/17/2011	CA2771099A1 Cancer cell apoptosis
03/17/2011	CA2770712A1 Heterocyclic compounds as janus kinase inhibitors
03/17/2011	CA2770252A1 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
03/16/2011	EP2295606A1 Expression analysis of KIAA nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
03/16/2011	EP2295604A2 Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
03/16/2011	EP2295598A1 Method and kit for detection of cancer, and therapeutic agent for cancer
03/16/2011	EP2295578A2 Cyp1b1 nucleic acids and methods of use
03/16/2011	EP2295560A1 Directed evolution of arginine deiminase for increased activity at physiological pH
03/16/2011	EP2295469A2 Monoclonal antibodies against claudin-18 for treatment of cancer
03/16/2011	EP2295456A1 Albumin fusion proteins
03/16/2011	EP2295447A1 GIPs, a family of polypeptides with transcription factor activity that interact with Goodpasture antigen binding protein
03/16/2011	EP2295442A2 Inhibitors of interleukin-1beta converting enzyme
03/16/2011	EP2295441A2 Novel Bicyclonucleoside and Oligonucleotide Analogue
03/16/2011	EP2295432A1 Process for the preparation of aminobenzimidazole derivatives
03/16/2011	EP2295427A1 Substituted pyrazolyl urea derivatives useful in the treatment of cancer
03/16/2011	EP2295426A1 Substituted pyrazolyl urea derivatives useful in the treatment of cancer
03/16/2011	EP2295424A1 Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
03/16/2011	EP2295416A2 Triazole compounds that modulate HSP90 activity
03/16/2011	EP2295415A1 Quinazoline derivatives
03/16/2011	EP2295413A1 Indazole compounds useful as protein kinase inhibitors
03/16/2011	EP2295412A1 Indazole compounds useful as protein kinase inhibitors
03/16/2011	EP2295410A1 HDAC inhibitor
03/16/2011	EP2295404A2 Substituted tetracycline compounds
03/16/2011	EP2295080A2 B-cell reduction using CD37-specific and CD20-specific binding molecules
03/16/2011	EP2295079A2 Method for treating inflammation
03/16/2011	EP2295078A2 Method for treating inflammation
03/16/2011	EP2295077A2 Identification of tumour-associated cell surface antigens for diagnosis and therapy
03/16/2011	EP2295074A1 Anti-neovasculature preparations for treating cancer

1 ... 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 ... 2211